侵袭性光滑念珠菌感染治疗策略的研究进展
摘要
近年来引起侵袭性念珠菌感染的病原体种类越来越多,其中光滑念珠菌已位居第二。抗真菌药物广泛使用使得光滑念珠菌耐药现象日趋严重,临床治疗易导致失败。目前,两种或多种抗真菌剂的联合治疗已在临床实施,同时各种研究性抗真菌药物尚处于临床前或临床开发阶段,其中部分抗真菌药物可能对耐唑类或棘白菌素类光滑念珠菌感染有效。该文从光滑念珠菌对常见抗真菌药物耐药着手,就新型抗真菌剂及联合使用抗真菌剂的研究进展做一综述,为指导临床合理使用抗真菌剂提供理论基础。
引文
[1]Nishikawa J L,Boeszoermenyi A,Vale-Silva L A,et al.Inhibiting fungal multidrug resistance by disrupting an activator-mediator interaction[J].Nature,2016,530(7591):485-9.
[2]Alexander B D,Johnson M D,Pfeiffer C D,et al.Increasing echinocandin resistance in Candida glabrata:clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations[J].Clin Infect Dis,2013,56(12):1724-32.
[3]Kolaczkowska A,Kolaczkowski M.Drug resistance mechanisms and their regulation in non-albicans Candida species[J].J Antimicrob Chemother,2016,71(6):1438-50.
[4]Pfaller M A,Castanheira M,Lockhart S R,et al.Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata[J].JClin Microbiol,2012,50(4):1199-203.
[5]Gohar A A,Badali H,Shokohi T,et al.Expression patterns of ABC transporter genes in fluconazole-resistant candida glabrata[J].Mycopathologia,2017,182(3-4):273-84.
[6]Vale-Silva L A,Moeckli B,Torelli R,et al.Upregulation of the adhesin gene EPA1 mediated by PDR1 in Candida glabrata leads to enhanced host colonization[J].m Sphere,2016,1(2):e00015-65.
[7]Hull C M,Bader O,Parker J E,et al.Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin Bboth harbor mutations in ERG2[J].Antimicrob Agents Chemother,2012,56(12):6417-21.
[8]Charlier C,El Sissy C,Bachelier-Bassi S,et al.Acquired flucytosine resistance during combination therapy with caspofungin and flucytosine for Candida glabrata cystitis[J].Antimicrob Agents Chemother,2015,60(1):662-5.
[9]Campoy S,Adrio J L.Antifungals[J].Biochem Pharmacol,2017,133:86-96.
[10]Hoekstra W J,Garvey E P,Moore W R,et al.Design and optimization of highly-selective fungal CYP51 inhibitors[J].Bioorg Med Chem Lett,2014,24(15):3455-8.
[11]Schell W A,Jones A M,Garvey E P,et al.Fungal CYP51 inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C krusei isolates clinically resistant to azole and echinocandin antifungal compounds[J].Antimicrob Agents Chemother,2017,61(3):e.01817-16.
[12]Break T J,Desai J V,Natarajan M,et al.VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and-resistant Candida albicans[J].J Antimicrob Chemother,2018,73(1):151-5.
[13]Singh S L,Rai R C,Sah S K.The catalytic subunit of the first mannosyltransferase in the GPI biosynthetic pathway affects growth,cell wall integrity and hyphal morphogenesis in Candida albicans[J].Yeast,2016,33(8):365-83.
[14]Gonzalez-Lara M F,Sifuentes-Osornio J.Drugs in clinical development for fungal infections[J].Drugs,2017,77(14):1505-18.
[15]Zhao M,Lepak A J,VanScoy B,et al.Pharmacokinetics and pharmacodynamics of APX001 against Candida spp in a neutropenic disseminated candidiasis mouse model[J].Antimicrob A-gents Chemother,2018,62(4):e02542-17.
[16]Lepak A J,Zhao M,VanScoy B,et al.Pharmacodynamics of a long-acting echinocandin,CD101,in a neutropenic invasive-candidiasis murine model using an extended-interval dosing design[J].Antimicrob Agents Chemother,2018,62(2):e02154-17.
[17]Ong V,Hough G,Schlosser M,et al.Preclinical evaluation of the stability,safety,and efficacy of CD101,a novel echinocandin[J].Antimicrob Agents Chemother,2016,60(11):6872-9.
[18]Pfaller M A,Messer S A,Motyl M R,et al.Activity of MK-3118,a new oral glucan syntase inhibitor,tested against Candida spp by two international methods(CLSI and EUCAST)[J].J Antimicrob Chemother,2013,68(4):858-63.
[19]Wiederhold N P,Najvar L K,Jaramillo R,et al.Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata[J].J Antimicrob Chemother,2018,73(2):448-51.
[20]Yamada E,Nishikawa H,Nomura N,et al.T-2307 shows efficacy in a murine model of Candida glabrata infection despite in vitro trailing growth phenomena[J].Antimicrob Agents Chemother,2010,54(9):3630-4.
[21]Wiederhold N P,Najvar L K,Fothergill A W,et al.The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrata[J].J Antimicrob Chemother,2016,71(3):692-5.
[22]Keller P,Müller C,Engelhardt I,et al.An antifungal benzimidazole derivative inhibits ergosterol biosynthesis and reveals novel sterols[J].Antimicrob Agents Chemother,2015,59(10):6296-307.
[23]Kaplanclkll Z A,Levent S,Osmaniye D,et al.Synthesis and anticandidal activity evaluation of new benzimidazole-thiazole derivatives[J].Molecules,2017,22(12):e2051.
[24]Chang Y L,Yu S J,Heitman J,et al.New facets of antifungal therapy[J].Virulence,2017,8(2):222-36.
[25]Denardi L B,Keller J T,Oliveira V,et al.Activity of combined antifungal agents against multidrug-resistant Candida glabrata strains[J].Mycopathologia,2017,182(9-10):819-28.
[26]Denardi L B,Mario D A,Loreto ES,et al.Synergistic effects of tacrolimus and azole antifungal compounds in fluconazole-susceptible and fluconazole-resistant Candida glabrata isolates[J].Braz JMicrobiol,2015,46(1):125-9.
[27]Li H,Chen Z,Zhang C,et al.Resistance reversal induced by a combination of fluconazole and tacrolimus(FK506)in Candida glabrata[J].J Med Microbiol,2015,64(Pt 1):44-52.
[28]Sharifzadeh A,Khosravi A R,Shokri H.Synergistic anticandidal activity of menthol in combination with itraconazole and nystatin against clinical Candida glabrata and Candida krusei isolates[J].Microb Pathog,2017,107:390-6.
[29]Samber N,Khan A,Varma A.Synergistic anti-candidal activity and mode of action of Mentha piperita essential oil and its major components[J].Pharm Biol,2015,53(10):1496-504.
[30]Sadowska B,Budzyńska A,Stochmal A,et al.Novel properties of Hippophae rhamnoides L twig and leaf extracts-anti-virulence action and synergy with antifungals studied in vitro on Candida spp model[J].Microb Pathog,2017,107:372-9.
[2]Alexander B D,Johnson M D,Pfeiffer C D,et al.Increasing echinocandin resistance in Candida glabrata:clinical failure correlates with presence of FKS mutations and elevated minimum inhibitory concentrations[J].Clin Infect Dis,2013,56(12):1724-32.
[3]Kolaczkowska A,Kolaczkowski M.Drug resistance mechanisms and their regulation in non-albicans Candida species[J].J Antimicrob Chemother,2016,71(6):1438-50.
[4]Pfaller M A,Castanheira M,Lockhart S R,et al.Frequency of decreased susceptibility and resistance to echinocandins among fluconazole-resistant bloodstream isolates of Candida glabrata[J].JClin Microbiol,2012,50(4):1199-203.
[5]Gohar A A,Badali H,Shokohi T,et al.Expression patterns of ABC transporter genes in fluconazole-resistant candida glabrata[J].Mycopathologia,2017,182(3-4):273-84.
[6]Vale-Silva L A,Moeckli B,Torelli R,et al.Upregulation of the adhesin gene EPA1 mediated by PDR1 in Candida glabrata leads to enhanced host colonization[J].m Sphere,2016,1(2):e00015-65.
[7]Hull C M,Bader O,Parker J E,et al.Two clinical isolates of Candida glabrata exhibiting reduced sensitivity to amphotericin Bboth harbor mutations in ERG2[J].Antimicrob Agents Chemother,2012,56(12):6417-21.
[8]Charlier C,El Sissy C,Bachelier-Bassi S,et al.Acquired flucytosine resistance during combination therapy with caspofungin and flucytosine for Candida glabrata cystitis[J].Antimicrob Agents Chemother,2015,60(1):662-5.
[9]Campoy S,Adrio J L.Antifungals[J].Biochem Pharmacol,2017,133:86-96.
[10]Hoekstra W J,Garvey E P,Moore W R,et al.Design and optimization of highly-selective fungal CYP51 inhibitors[J].Bioorg Med Chem Lett,2014,24(15):3455-8.
[11]Schell W A,Jones A M,Garvey E P,et al.Fungal CYP51 inhibitors VT-1161 and VT-1129 exhibit strong in vitro activity against Candida glabrata and C krusei isolates clinically resistant to azole and echinocandin antifungal compounds[J].Antimicrob Agents Chemother,2017,61(3):e.01817-16.
[12]Break T J,Desai J V,Natarajan M,et al.VT-1161 protects mice against oropharyngeal candidiasis caused by fluconazole-susceptible and-resistant Candida albicans[J].J Antimicrob Chemother,2018,73(1):151-5.
[13]Singh S L,Rai R C,Sah S K.The catalytic subunit of the first mannosyltransferase in the GPI biosynthetic pathway affects growth,cell wall integrity and hyphal morphogenesis in Candida albicans[J].Yeast,2016,33(8):365-83.
[14]Gonzalez-Lara M F,Sifuentes-Osornio J.Drugs in clinical development for fungal infections[J].Drugs,2017,77(14):1505-18.
[15]Zhao M,Lepak A J,VanScoy B,et al.Pharmacokinetics and pharmacodynamics of APX001 against Candida spp in a neutropenic disseminated candidiasis mouse model[J].Antimicrob A-gents Chemother,2018,62(4):e02542-17.
[16]Lepak A J,Zhao M,VanScoy B,et al.Pharmacodynamics of a long-acting echinocandin,CD101,in a neutropenic invasive-candidiasis murine model using an extended-interval dosing design[J].Antimicrob Agents Chemother,2018,62(2):e02154-17.
[17]Ong V,Hough G,Schlosser M,et al.Preclinical evaluation of the stability,safety,and efficacy of CD101,a novel echinocandin[J].Antimicrob Agents Chemother,2016,60(11):6872-9.
[18]Pfaller M A,Messer S A,Motyl M R,et al.Activity of MK-3118,a new oral glucan syntase inhibitor,tested against Candida spp by two international methods(CLSI and EUCAST)[J].J Antimicrob Chemother,2013,68(4):858-63.
[19]Wiederhold N P,Najvar L K,Jaramillo R,et al.Oral glucan synthase inhibitor SCY-078 is effective in an experimental murine model of invasive candidiasis caused by WT and echinocandin-resistant Candida glabrata[J].J Antimicrob Chemother,2018,73(2):448-51.
[20]Yamada E,Nishikawa H,Nomura N,et al.T-2307 shows efficacy in a murine model of Candida glabrata infection despite in vitro trailing growth phenomena[J].Antimicrob Agents Chemother,2010,54(9):3630-4.
[21]Wiederhold N P,Najvar L K,Fothergill A W,et al.The novel arylamidine T-2307 demonstrates in vitro and in vivo activity against echinocandin-resistant Candida glabrata[J].J Antimicrob Chemother,2016,71(3):692-5.
[22]Keller P,Müller C,Engelhardt I,et al.An antifungal benzimidazole derivative inhibits ergosterol biosynthesis and reveals novel sterols[J].Antimicrob Agents Chemother,2015,59(10):6296-307.
[23]Kaplanclkll Z A,Levent S,Osmaniye D,et al.Synthesis and anticandidal activity evaluation of new benzimidazole-thiazole derivatives[J].Molecules,2017,22(12):e2051.
[24]Chang Y L,Yu S J,Heitman J,et al.New facets of antifungal therapy[J].Virulence,2017,8(2):222-36.
[25]Denardi L B,Keller J T,Oliveira V,et al.Activity of combined antifungal agents against multidrug-resistant Candida glabrata strains[J].Mycopathologia,2017,182(9-10):819-28.
[26]Denardi L B,Mario D A,Loreto ES,et al.Synergistic effects of tacrolimus and azole antifungal compounds in fluconazole-susceptible and fluconazole-resistant Candida glabrata isolates[J].Braz JMicrobiol,2015,46(1):125-9.
[27]Li H,Chen Z,Zhang C,et al.Resistance reversal induced by a combination of fluconazole and tacrolimus(FK506)in Candida glabrata[J].J Med Microbiol,2015,64(Pt 1):44-52.
[28]Sharifzadeh A,Khosravi A R,Shokri H.Synergistic anticandidal activity of menthol in combination with itraconazole and nystatin against clinical Candida glabrata and Candida krusei isolates[J].Microb Pathog,2017,107:390-6.
[29]Samber N,Khan A,Varma A.Synergistic anti-candidal activity and mode of action of Mentha piperita essential oil and its major components[J].Pharm Biol,2015,53(10):1496-504.
[30]Sadowska B,Budzyńska A,Stochmal A,et al.Novel properties of Hippophae rhamnoides L twig and leaf extracts-anti-virulence action and synergy with antifungals studied in vitro on Candida spp model[J].Microb Pathog,2017,107:372-9.